BeOne Medicines said the FDA granted accelerated approval for its drug Beqalzi (sonrotoclax) in relapsed or refractory mantle cell lymphoma, positioning the company to challenge incumbents including AbbVie and Roche’s Venclexta. The regulatory action adds a new late-line option in a space where timing and mechanism differences can influence treatment sequencing. The approval comes as BeOne seeks to establish momentum for additional clinical programs built around its BCL2-targeting approach. For investors and clinicians, the key near-term issue is how BeOne’s label translates to real-world adoption versus existing regimens and whether confirmatory study plans align with FDA expectations. The accelerated path also highlights how the FDA continues to use interim efficacy signals in aggressive hematologic malignancies when the unmet need is high and trials can move quickly.